BTK and B-cell chronic lymphocytic leukemia: If these data are replicated in larger cohorts, it may have implications for the role of BTK mutation testing in the future as well as the choice of covalent BTKis, particularly if pirtobrutinib receives regulatory approval in R/R CLL patients previously treated with a covalent BTKi.